Stifel stays Buy on Palvella: multiple 'pipeline-in-a-product' opportunities

March 31, 2026 3:06 PM

Stifel analyst Annabel Samimy reiterated a Buy rating and $250.00 price target on Palvella Therapeutics (NASDAQ: PVLA)The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found